PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patien...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Rolfes, Verena, Idel, Christian, Pries, Ralph, Plötze-Martin, Kirstin, Habermann, Jens, Gemoll, Timo, Bohnet, Sabine, Latz, Eicke, Ribbat-Idel, Julika, Franklin, Bernardo S., Wollenberg, Barbara
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007942/
https://ncbi.nlm.nih.gov/pubmed/29937998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25446
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak